Coenzyme Q10 in health and disease

European Journal of Clinical Nutrition

Volumn 53, Issue 10, 1999, Pages 764-770

  Overvad, K ^a,b   Diamant, B ^a   Holm, L ^a   Holmer G ^a   Mortensen, S A ^a   Stender, S ^a  

^a Danish Nutrition Council   (Denmark)

^b NONE   (Denmark)

Author keywords

Cardiovascular diseases; Coenzyme Q10; Health; Physical activity; Supplementation

Indexed keywords

UBIDECARENONE; UBIQUINONE;

BIOSYNTHESIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DIETARY INTAKE; HEALTH STATUS; HEART; HEART FAILURE; HEMODYNAMICS; HUMAN; MEDICAL LITERATURE; PHYSICAL ACTIVITY; REVIEW; CHEMISTRY; GENERAL ASPECTS OF DISEASE; HEALTH; NEOPLASM; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DISEASE; HEALTH; HUMANS; NEOPLASMS; UBIQUINONE;

EID: 0032589681     PISSN: 09543007     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1600880     Document Type: Review

References (60)

1. 10 and vitamin E on the peroxidation of human low density lipoprotein subfractions. PNAS 92, 9388-9391.
2. Alleva R, Scararmucci A, Mantero F, Bompadre S, Leoni L & Littarru GP (1997): The protective role of ubiquinol - 10 against formation of lipid hydroperoxides in human seminal fluids. Molec. Asp. Med. 18, 221-228.
3. 10 preserves plasma ubiquinone levels in patients with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int. J. Clin. Lab. Res. 24, 171-176.
4. Battino M, Amadio E, Oradel A & Littarru GP (1997): Metabolic and antioxidant markers in the plasma of sportsmen from a Mediterranean town performing non-agonistic activity. Molec. Asp. Med. 18, 241-245.
5. Bowry VW, Stanley KK & Stocker R (1992): High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. PNAS 89, 10316-10320.
6. 2max, and lipid peroxidation in trained cyclists. Int. J. Sport. Med. 1, 353-363.
7. 10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann. Thorac. Surg. 58, 1427-1432.
8. 10 of tissue reperfusion injury during abdominal aortic cross-clamping. J. Cardiovasc. Surg. 37, 229-235.
9. Crane FL, Hatefi Y, Lester RL & Widmer C (1957): Isolation of quinone from beef heart and beef mitochondria. Biochem. Biophys. Acta 25, 220-221.
10. 10, pretreatment. J. Thorac. cardiovasc. surg. 111 (No. 2), 443-450.
11. 10 on essential arterial hypertension. Curr. Ther. Res. 47, 841-845.
12. Ernster L & Forsmark-Andrée P (1993): Uniquinol: an endogenous antioxidant in aerobic organisms. Clin. Investig. 71, 60-65.
13. max 272 mμ). Biochem. J. 59, 558-566.
14. 10) on muscular dystrophies and neurogenic atrophies. Biochem. Biophys. Acta 1271, 281-286.
15. 10. Proc. Nat. Acad. Sci. Amsterdam: Elsevier, 82, 901-904.
16. 10. In: Vitamins and cancer prevention. New York: Wiley-Liss, pp. 103-110.
17. 10 in human tissues. Arch Biochem. Biophys. 93, 211-213.
18. 10) på Marginal paradonitis. Tandlaegehladet 98, 287-292.
19. 10 on adult periodontitis. Mol. Asp. Med. 15, 241-248.
20. 10 in patients with stable angina pectoris. In: Folkers K & Yamamura Y, (eds.). Biomedical and Clinical Aspects of Coenzyme Q Amsterdam: Elsevier Vol 4, pp. 291-301.
21. 10 as an adjunctive in the treatment of chronic congestive heart failure. J. Cardiac. Failure. Amsterdam: Elsevier, 1, 101-107.
22. 10 on periodontal disease. In: K Folkers & Y Yamamura, (eds). Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier, Vol 3, pp. 109-119.
23. 10 in heart failure. In: K Folkers & Y Yamamura, Biomedical and Clinical Aspects of Coenzyme Q. Vol 5, pp. 315-323.
24. 10 during heart surgery. Clin. Invest. Amsterdam: Elsevier, 71, 155-161.
25. 10 supplementation on the oxidation resistance of human VLDL + LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Rad. Biol. Med. 22, 1195-1202.
26. 10 on exercise tolerance in chronic stable angina pectoris. Am. J. Cardio. 56, 247-251.
27. 10) in man. In: K Folkers & Y Yamamura, (eds). Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier, Vol 5, pp. 241-246.
28. Karlsson J, Diamant B, Theorell H & Folkers K (1993): Uniquinone and alpha tocopherol in plasma; means of translocation or depot. Clin. Invent. 71 (Suppl), S84-S91.
29. Laaksonen R, Fogelholm M, Himberg JJ, Laakso J & Salorinne V (1995): Uniquinone supplementation and exercise capacity in trained young and older men. Eur. J. Appl. Physiol. 72, 95-100.
30. 10. Proc. Natl. Acad. Sci. USA 82, 4240-4244.
31. 10 on sperm mobility and function. Molec. Asp. Med. 18, 213-219.
32. 10. Biochem. Biophys. Res. Commun. 199, 1504-1508.
33. Malm C, Svensson M, Sjöberg B, Ekblom B & Sjödin B (1996): Supplementation with ubiquinone-10 causes cellular damage during intense exercise. Acta Physiol. Scand. 157, 511-512.
34. Malm C, Svensson M, Ekblom B & Sjödin B (1997): Effects of uniquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol. Scand. 161, 379-384.
35. 10 in patients with chronic stable effort angina and moderate heart failure. Curr. Ther. Res. 41, 923-932.
36. 10 results in increased levels of uniquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochem. Biophys. Acta 1126(3), 247-254.
37. 10 therapy in patients with congestive heart failure: a long-term multicenter randomised study. Clin. Invest. 71, 134-136.
38. Morisco C, Nappi A, Argenziano L, Sarno D, Fonatana D, Imbriaco M (1994): Noninvasive evaluaton of cardian hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Molec. Asp. Med. 15, 155-163.
39. Mortensen SA (1989): Endomyocardial biopsy. Technical aspects and indications. Dan. Med. Bull. 36, 507-532.
40. 10 during treatment with HMG-CoA reductase inhibitors. Molec. Asp. Med. 18 (Suppl), S137-S144.
41. Olson RE & Rudney H (1983): Biosynthesis of ubiquinone. Vitam. Horm. 40, 1-43.
42. 10 (Ubichinon) bei der Langzeitbehandlung de dilatativen Kardiomyopathie. Z. Kardiol. 78, 360-365.
43. 10 in left ventricular function in patients with dilative cardiomyopathy. Curr. Ther. Res. 49, 878-886.
44. 10 on the exercise tolerance of middle-aged untrained men. Int. J. Sport. Med. 16, 421-427.
45. Ramasarma T (1985): Natural occurrence and distribution of coenzyme Q. In: G Lenaz (ed). Coenzyme Q. Biochemistry, Biogenetics and Clinical Applications of Uniquinone 1985; John Wiley and Sons, New York, pp. 67-81.
46. 10 in ischemic cardiomyopathy. In: Folkers K, Littarru GP & Yamagami T (eds). Biomedical and Clinical Aspects of Coenzyme Q Amsterdam: Elsevier 1991; Vol 6, pp. 321-326.
47. 10 on ischemia-induced ST-segment depression: a double-blind, placebo-controlled crossover study. In: K Folkers, & Y Yamamura (eds). Biomedical and Clinical Aspects of Coenzyme Q 1986; Vol 5, pp. 358-394.
48. 10 in patients with moderate heart failure and chronic stable effort angina. In: Folkers K, Littarru GP (eds). Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier 1991; Vol 6, pp. 327-338.
49. 10 inpatients with acute myocardial infarction. Cardiovasc. Drugs Ther. 12, 347-353.
50. Snider IP, Bazzarre TL, Murdoch SD & Goldfarb A (1992): Effects of coenzyme athletic performance system as an ergogenic aid on endurance performance to exhaustion. Int. J. Sport. Med. 2, 272-286.
51. Stocker R, Thomas SR & Neuzil J (1996): Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transistion metal-dependent oxidation initiation. Arterioscler. Thromb. Vasc. Biol. 16, 687-696.
52. 10 in man. Int. J. Clin. Pharmac. Ther. Toxicol. 24, 536-541.
53. 10 on physical performance and recovery in myocardial failure. In: Folkers K & Yamamura Y (eds). Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam : Elsevier 1986; Vol 5, pp. 371-377.
54. 10 in normal Danish food ingredients. Int. J. Vitam. Nutr. Res. 67, 123-129.
55. 10 affect aerobic capacity in endurance athletes. Int. J. Sport. Nutr. 7, 197-206.
56. 10. Res Commun. Chem. Pathol. Pharmac. 14, 715-719.
57. 10 therapy and exercise duration in stable angina. In: Folkers K, Littarru GP & Yamagami T (eds). Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier 1991; Vol 6, pp. 339-348.
58. 10 on the impaired aerobic function in middle aged women without organic disease. In: Folkers K, Littarru G, Yamagami T (eds). Biomedical and Clinical Aspects of Coenzyme. Amsterdam: Elsevier 1991; Vol 6, pp. 513-520.
59. 10 on essential hypertension, a double blind controlled study. In: Folkers K, Yamamura Y (eds). Biochemical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier. 1986; Vol 5, pp. 337-343.
60. 10 on the exercise performance of cross-country skiers. Molec. Asp. Med. 18 (Suppl), S283-S290.